Coronavirus Infection

People in the colchine group will be given a starting dose of 1.2 mg followed, by 0.6mg after 2 hours if they do not have significant gastrointestinal symptoms, on day 1. After that, they will take colchicine 0.6mg twice a day for 14 days or until discharged or release from the hospital.

Colchicine

COVID Patients in this arm will receive usual care COVID19 treatment and will not receive colchine.

Usual Care

Maimonides Medical Center

COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19

COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19 (the COMBAT-COVID-19 Pilot Study)

Withdrawal of beta blockers and ACE inhibitors

Dilated Cardiomyopathy

withdrawal of beta blocker and ACE inhibitors

withdrawal

STANDARD OF CARE, NO WITHDRAWAL OF MEDICAL THERAPY

standard of CARE

Royal Victoria Hospital

Withdrawal of Medication in Recovered DCM

Withdrawal of Beta- Blockers and ACE Inhibitors After Left Ventricular Systolic Function Recovery in Patient With Dilated Cardiomyopathy: A Randomized Control Trial.

Nadia Giannetti

Chief, Division of Cardiology, Director of Heart Function Clinic

McGill University

McGill University Health Centre/Research Institute of the McGill University Health Centre

Jewish General Hospital

clenbuterol: Clenbuterol 20 mcg tablets uptitrated from 20 mcg PO TID to a maximally tolerated dose not to exceed 700 mcg PO TID. Patients will then be switched to the equivalent dose of clenbuterol liquid 59 mcg/ml PO TID. Clenbuterol will be administered for a minimum of 3 months and a maximum of 12 months.

LVAD and Clenbuterol

Sex: Female, Male

Region of Enrollment

Percent of Subjects Who Experience LVAD Removal and Subsequent Freedom From Mechanical Circulatory Support or Heart Transplantation for 1-year After Explantation

The Number of Evaluable Subjects Meeting Explant Criteria and Subsequently Explanted

Number of Subjects Who Received Maximum Target Dose of Clenbuterol

Time from LVAD placement to explant for the single participant who achieved explant

Time to Device Explant for Subjects Meeting Explant Criteria Defined in the Protocol

Absolute Change in Left Ventricular Ejection Fraction From Explant to 18 Months Following Device Explant

Absolute Percent Change in Serum Creatinine and Aspartate Transaminase (AST) From Baseline to Week 8 Post Implant

Scale 0 - 100 where 0 is worst possible health state and 100 is perfect health.

Mean Change in EuroQoL Visual Analog Scale (EQ5D-VAS) From Baseline to 6 Months and 1 Year Following Device Implant

Scale 0 - 105 (0- 5 on 21 items) where 0 means heart failure has not limited daily life at all and high scores mean that daily functions are greatly limited.

Mean Change in Minnesota Living With Heart Failure Questionnaire (MLHFQ) From Baseline to 6 Months

Mean Change in Left Ventricular Ejection Fraction From Device Implant to Completion of Clenbuterol Therapy

Absolute Percent Change in Serum Creatinine and Aspartate Transaminase (AST) From Baseline to Week 8 Post Clenbuterol

Mean Change in Minnesota Living With Heart Failure Questionnaire (MLHFQ) From Baseline to 1 Year Following Device Implant

Participants, all of whom received LVAD implantation, were to begin clenbuterol treatment 12 weeks after their implantation.
Clenbuterol 20 mcg tablets uptitrated from 20 mcg PO TID to a maximally tolerated dose not to exceed 700 mcg PO TID. Patients will then be switched to the equivalent dose of clenbuterol liquid 59 mcg/ml PO TID. Clenbuterol will be administered for a minimum of 3 months and a maximum of 12 months.

LVAD and (Intended) Clenbuterol

LVAD Implantation Required for 4 Months

Clenbuterol Treatment - up to 12 Months

Francis Pagani

Heart Failure

Clenbuterol 20 mcg tablets uptitrated from 20 mcg PO TID to a maximally tolerated dose not to exceed 700 mcg PO TID. Patients will then be switched to the equivalent dose of clenbuterol liquid 59 mcg/ml PO TID. Clenbuterol will be administered for a minimum of 3 months and a maximum of 12 months.

clenbuterol

Georgetown Hospital

Northwestern University

University of Michigan Health System

Montefiore Medical Center

Ohio State University

University of Pennsylvania

Texas Heart Institute

Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure

Harefield Recovery Protocol Study (HARPS): A Nonrandomized, Open Label, Multicenter Evaluation of Potential Recovery of Heart Function in Patients With Refractory Chronic Heart Failure by Treatment With Combination of Left Ventricular Assist Device (LVAD), Drugs to Induce Maximal Reverse Remodeling and the Beta-2 Adrenergic Receptor Agonist Clenbuterol.

Francis D. Pagani

Professor of Cardiac Surgery

Georgetown University

University of Minnesota

Thoratec Corporation

Sleep Apnea

Cardiovascular Diseases

CPAP(Continuous Positive Airway Pressure)

Hospital Universitario Txagorritxu

Cardiac Function After CPAP Therapy in Patients With Chronic Heart Failure and Sleep Apnea. A Multicenter Study

digoxin/atrofi

COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19

Withdrawal of Medication in Recovered DCM

Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure

Cardiac Function After CPAP Therapy in Patients With Chronic Heart Failure and Sleep Apnea. A Multicenter Study

Bilim tarafından desteklenen en eksiksiz şifalı otlar veritabanı